2-(Cyclohexanecarbonyl-amino)-malonamide | 890403-14-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-(Cyclohexanecarbonyl-amino)-malonamide
• 英文别名: 2-(Cyclohexanecarbonylamino)propanediamide
• CAS: 890403-14-2
• 化学式: C₁₀H₁₇N₃O₃
• 分子量: 227.263
• InChiKey: OMTRBQKBWPWKBC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  115
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(Cyclohexanecarbonyl-amino)-malonamide 在 硫酸 、 三氯氧磷 作用下， 反应 1.0h， 生成 5-Amino-2-cyclohexyl-oxazole-4-carboxylic acid amide
  参考文献：
  名称：

  Evolution of the Thienopyridine Class of Inhibitors of IκB Kinase-β:  Part I:  Hit-to-Lead Strategies

  摘要：

  High-throughput screening is routinely employed as a method for the identification of novel hit structures. Large numbers of active compounds are typically procured in this way and must undergo a rigorous validation process. This process is described in detail for a collection of screening hits identified as inhibitors of I kappa B kinase-beta (IKK beta), a key regulatory enzyme in the nuclear factor-kappa B (NF-kappa B) pathway. From these studies, a promising hit series was selected. Subsequent lead generation activities included the development of a pharmacophore hypothesis and structure-activity relationship (SAR) for the hit series. This led to the exploration of related scaffolds offering additional opportunities, and the various structural classes were comparatively evaluated for enzyme inhibition, selectivity, and drug-like properties. A novel lead series of thienopyridines was thereby established, and this series advanced into lead optimization for further development.

  DOI：

  10.1021/jm0510979
• 作为产物：
  描述：

  Cyclohexanecarboxylic acid dicyanomethyl-amide 在 硫酸 作用下， 以800 mg的产率得到2-(Cyclohexanecarbonyl-amino)-malonamide
  参考文献：
  名称：

  Evolution of the Thienopyridine Class of Inhibitors of IκB Kinase-β:  Part I:  Hit-to-Lead Strategies

  摘要：

  High-throughput screening is routinely employed as a method for the identification of novel hit structures. Large numbers of active compounds are typically procured in this way and must undergo a rigorous validation process. This process is described in detail for a collection of screening hits identified as inhibitors of I kappa B kinase-beta (IKK beta), a key regulatory enzyme in the nuclear factor-kappa B (NF-kappa B) pathway. From these studies, a promising hit series was selected. Subsequent lead generation activities included the development of a pharmacophore hypothesis and structure-activity relationship (SAR) for the hit series. This led to the exploration of related scaffolds offering additional opportunities, and the various structural classes were comparatively evaluated for enzyme inhibition, selectivity, and drug-like properties. A novel lead series of thienopyridines was thereby established, and this series advanced into lead optimization for further development.

  DOI：

  10.1021/jm0510979

文献信息

• Evolution of the Thienopyridine Class of Inhibitors of IκB Kinase-β:  Part I:  Hit-to-Lead Strategies
  作者：Tina Morwick、Angela Berry、Janice Brickwood、Mario Cardozo、Katrina Catron、Molly DeTuri、Jonathan Emeigh、Carol Homon、Matt Hrapchak、Stephen Jacober、Scott Jakes、Paul Kaplita、Terence A. Kelly、John Ksiazek、Michel Liuzzi、Ronald Magolda、Can Mao、Daniel Marshall、Daniel McNeil、Anthony Prokopowicz、Christopher Sarko、Erika Scouten、Cynthia Sledziona、Sanxing Sun、Jane Watrous、Jiang Ping Wu、Charles L. Cywin

  DOI：10.1021/jm0510979

  日期：2006.5.1

  High-throughput screening is routinely employed as a method for the identification of novel hit structures. Large numbers of active compounds are typically procured in this way and must undergo a rigorous validation process. This process is described in detail for a collection of screening hits identified as inhibitors of I kappa B kinase-beta (IKK beta), a key regulatory enzyme in the nuclear factor-kappa B (NF-kappa B) pathway. From these studies, a promising hit series was selected. Subsequent lead generation activities included the development of a pharmacophore hypothesis and structure-activity relationship (SAR) for the hit series. This led to the exploration of related scaffolds offering additional opportunities, and the various structural classes were comparatively evaluated for enzyme inhibition, selectivity, and drug-like properties. A novel lead series of thienopyridines was thereby established, and this series advanced into lead optimization for further development.